RHYTHM PHARMACEUTICALS, INC. (RYTM) Stock
RYTM has an Alpha Score of 47 out of 100 (weak), computed on Nov 8, 2026 from 2 of 4 sub-scores. 7 of the hedge funds AlphaScala tracks reported RYTM in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $140.30M. Company insiders reported 0 open-market buys and 20 sales on SEC Form 4 in the 90 days to Nov 9, 2026.
What is RYTM's Alpha Score?
How it works →Alpha Score of 47 reflects weak overall profile with strong momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 8, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own RYTM?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.26M | $140.30M | -11% |
| Point72 Steve Cohen | 414K | $45.99M | -51% |
| Millennium Management Israel Englander | 317K | $35.17M | -30% |
| Duquesne Family Office Stanley Druckenmiller | 204K | $22.61M | NEW |
| Renaissance Technologies Jim Simons (founder) | 68K | $7.58M | -74% |
| D.E. Shaw David Shaw | 30K | $3.35M | -8% |
| Marshall Wace | 8K | $907.6K | -15% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are RHYTHM PHARMACEUTICALS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 14, 26 | Meeker David P | President and CEO | SELL | 6.4K | $655K |
| Sep 14, 26 | Meeker David P | President and CEO | SELL | 30.7K | $3.1M |
| Sep 14, 26 | Meeker David P | President and CEO | SELL | 8.7K | $900K |
| Sep 14, 26 | Meeker David P | President and CEO | SELL | 1.8K | $190K |
| Sep 14, 26 | Meeker David P | President and CEO | SELL | 2.3K | $242K |
| Aug 31, 26 | Smith Hunter C | Chief Financial Officer | SELL | 23.1K | $2.4M |
| Aug 31, 26 | Smith Hunter C | Chief Financial Officer | SELL | 11.5K | $1.2M |
| Aug 31, 26 | Smith Hunter C | Chief Financial Officer | SELL | 28.2K | $3.0M |
| Aug 13, 26 | Lee Jennifer Kayden | EVP, Head of North America | SELL | 75.8K | $8.9M |
| Aug 13, 26 | Garfield Alastair | Chief Scientific Officer | SELL | 2.0K | $233K |
SEC Form 4 filings as of Nov 9, 2026
See cluster-buy signals across all tickers →What are RYTM's key statistics?
Key statistics as of Nov 8, 2026
How does RYTM's valuation compare with the Healthcare sector?
| Metric | RYTM | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -69.03% | 3.62% | 174 |
| Return on equity | -83.68% | 2.96% | 200 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
RYTM price chart
Powered by TradingViewWhat does RHYTHM PHARMACEUTICALS, INC. do?
Rhythm Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases, particularly those involving hyperphagia and severe obesity. Its lead product, IMCIVREE (setmelanotide), is a precision medicine targeting rare melanocortin-4 receptor (MC4R) diseases, such as POMC deficiency and Bardet-Biedl syndrome, where traditional weight-loss treatments often prove ineffective. The company addresses unmet needs in rare disease obesity, a niche insulated from broader market dynamics in weight management drugs. Rhythm Pharmaceuticals Inc. operates in the pharmaceuticals and biotech sector, emphasizing treatments for genetic disorders that cause uncontrollable hunger and related complications. Headquartered in Boston, Massachusetts, and founded in 2008, it serves patients through specialized healthcare channels, positioning itself as a leader in rare disease therapies within the neuroendocrine space.